NIH Spends $1.4 Billion a Year on Startup Grants — and 40% Goes to First-Timers

The National Institutes of Health pours roughly $1.4 billion a year into SBIR and STTR grants for small businesses — and about 40 percent of those awards go to first-time recipients. Adam Sorkin, a small business policy manager at NIH, put the invitation plainly during an Oct. 16 virtual panel: "So if you're new and just getting started, I really hope you're not dissuaded from working with us. We're very used to working with companies and entrepreneurs like yourself who are just entering the program."

The panel, hosted by UNeMed — the tech transfer organization for the University of Nebraska at Omaha and the University of Nebraska Medical Center — ran as part of UNeMed's Innovation Week. Various NIH institutes presented their programs. The advice applies to any entrepreneur pursuing SBIR/STTR funding from any federal agency, not just health-focused ones.

What do the programs actually fund?

Congress briefly shuttered SBIR/STTR this spring while it worked to reauthorize the programs, often nicknamed "America's seed fund." Some rules have changed since. Agencies still want applicants.

The money exists to turn highly technical, specialized technology into market-ready products. Startups emerging from universities are a natural fit, but any startup can apply and be eligible. Federal agencies fund a wide range of technologies. NIH focuses on medical breakthroughs such as vaccines, drugs and medical devices. Digital health products and software solutions also qualify, given how integral computers have become to healthcare.

The strongest selling point is structure: the grants are non-dilutive, meaning federal agencies take no equity stake in the startup. The takeaway is free money, in the literal sense — if the application survives scrutiny.

What does the return on investment look like?

Data from the National Institute of Neurological Disorders and Stroke (NINDS) covering 2008-2016 makes the case. "One out of four of the companies (funded then through SBIR/STTR) have exited already through an IPO, a license deal or a merger," said Annette Gilchrist, program director for drug development at NINDS. "Over $15 billion in private and public funding have followed the $420 million that we put in (in that time)."

Run the numbers: roughly $36 of follow-on capital for every federal dollar invested, spread across a decade. That figure covers a period ending nearly a decade ago, though, and NINDS has not published comparable figures since. Even so, a 25 percent exit rate for seed-funded companies is striking by venture standards.

What mistakes sink academic applicants?

The NIH managers flagged one error repeatedly: academics treat SBIR/STTR as a research grant rather than a commercialization vehicle. Stephanie Davis, small business program coordinator at the National Heart, Lung and Blood Institute, used a drug example.

"For example, if you are developing a new therapeutic for asthma, one of the things that we're going to be looking for is to support things such as preclinical screening, testing, and development of a drug," Davis said. "We're not necessarily going to be looking for a very in-depth identification of the molecular pathways that this drug activates."

In short, the agencies want products moving toward markets, not papers moving toward journals.

Why does the team matter as much as the idea?

The second common mistake is a thin team. Applicants need to bring in people — even consultants — who cover expertise the founders lack, and agencies check whether they do. "Maybe you're great at discovery, but you haven't done a lot of neuroscience and you're not familiar with the animal models for epilepsy," Gilchrist said. "You have somebody join your team even as a consultant that has that expertise, and it is clear within the application that you have already defined who is going to be your role person in that particular area."

The application itself must name those people and their roles. Vague promises of future hiring do not pass.

What changed after reauthorization?

Two procedural rules now carry real weight. First, overlapping interest among federal agencies in similar technologies means applicants should contact SBIR/STTR program managers early — before filing — so a misdirected or misaligned application can be fixed in time. Second, late applications are no longer accepted at all. Miss the deadline and the application is dead, regardless of quality.

For Nebraska's tech transfer offices and university spinouts, the calculus is straightforward: a reauthorized program, $1.4 billion a year at NIH alone, no equity given up — provided founders apply on time and pitch a business, not a research agenda.